BugRx is a new biotechnology company in Cambridge, Massachusetts, developing human monoclonal antibodies made in insect cells. The CEO, Dr. Bugsbunny, has convened a Board Meeting to discuss research proposals and budgets. The VP of Research & Development, Karen Hucklebug, gives an update on the Factor 801A program. Factor 801A is new signal transduction molecule that is important for the growth of ovarian cancer cells. She explains that the structure of the antibody binding to 810A has been finalized and production is on schedule in Luv Bug, Ireland. The CMO, Dr. David Sprayberry, reminds the Board that several pathologists have reported high levels of Factor 801A in ovarian cancer cells and it is a significant prognostic factor. The American Cancer Society estimates that 14,070 women died of ovarian cancer in the United States in 2018 Propose a PK protocol (~100 words) to study the distribution of the antibody to Factor 801A after IP injection in mice.
BugRx is a new
Propose a PK protocol (~100 words) to study the distribution of the antibody to Factor 801A after IP injection in mice.
…
Step by step
Solved in 2 steps
